- By admin
- By June 15, 2026
Q3 2026 MD&A | Management's discussion and analysis of financial condition and results of operations
Page 1 / 39
Zoom 100%
Q3 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations
Earlier from Helix Biopharma
- Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
- Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
- Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
- Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy